Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Infection with Helicobacter pylori (H. pylori) is now recognized as a major factor in the pathogenesis of gastric disease, and the successful therapy regimens require a combination of H2 blockers with gastroprotective and antimicrobial agents. Ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene) amino]-4-thiazolyl] methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) is the only drug combining acid-suppressant activity with remarkable gastroprotective and anti-H. pylori properties. The drug not only displays a potent anti-H. pylori activity alone, but also exerts a strong potentiating effect on the efficacy of antimicrobial agents commonly used for H. pylori eradication, and the successful ulcer therapy with ebrotidine induces a significant (4-fold) increase in the H. pylori aggregation titer of gastric mucin. Moreover, the drug exhibits a strong inhibitory effect on H. pylori urease activity, the extent of which exceeds that of ranitidine, omeprazole and lansoprazole. Ebrotidine has also been demonstrated to exert a potent inhibitory action on the enzymatic activities directed towards mucus perimeter of gastric mucosal defense, causing a marked inhibition of H. pylori protease, lipase and phospholipase A2 activities. Another important property of ebrotidine is its ability to efficiently counteract the disruptive effects of H. pylori lipopolysaccharide on the integrity of gastric epithelium. This includes countering the interference by the lipopolysaccharide in mucosal integrin receptor interaction with proteins of extracellular matrix and the reversal of H. pylori disruptive effect on the binding of mucin to its gastric epithelial receptor. Furthermore, most recent data indicate that ebrotidine has the ability to reverse the impairment caused by H. pylori in feedback inhibition of gastrin release by somatostatin. This activity of ebrotidine apparently stems from the drug's ability to counter the untoward effect of H. pylori on the binding of somatostatin to its specific receptor on the gastric mucosal G-cells. The unique combination of acid suppressant, gastroprotective and anti-H. pylori activities makes ebrotidine a drug of choice in the treatment of gastric disease caused by H. pylori.
Slomiany
B L
BL
Research Center, University of Medicine and Dentistry of New Jersey, Newark, USA.
Piotrowski
J
J
Slomiany
A
A
D000818:Animals; D001557:Benzenesulfonates / Q000494:pharmacology*; D005752:Gastric Mucins / Q000502:physiology; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000201:enzymology; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D008049:Lipase / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D010447:Peptide Hydrolases / Q000378:metabolism; D011135:Polysaccharides, Bacterial / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism; D013429:Sulfatases / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*; D014510:Urease / Q000378:metabolism
D001557:Benzenesulfonates; D005752:Gastric Mucins; D006635:Histamine H2 Antagonists; D011135:Polysaccharides, Bacterial; D017481:Receptors, Somatostatin; D013844:Thiazoles; D008049:Lipase; D013429:Sulfatases; C022758:glycosulphatase; D010447:Peptide Hydrolases; D014510:Urease; C075156:ebrotidine